Biotech by one-year price change
How far the share price has moved over the last 52 weeks.
Moderna leads the 24 biotech ranked by one-year price change, at +755%, ahead of Kodiak Sciences (+396%) and Twist Bioscience (+340%). Figures as of 18 Nov 2026, 14:31 UTC, from Yahoo Finance quotes.
Key facts
- Companies ranked
- 24
- First
- Moderna+755%
- Median
- +40.0%
- Combined market value
- CHF 707.8B
- Countries
- 5
Market values as of .
All countries▾
All sectors▾
Biotech▾
| # | Company | 1 year ↓ | Market cap | Price | Today | 1 year | Price, 30 days | Country |
|---|---|---|---|---|---|---|---|---|
| 1 | ModernaMRNA · Health Care | +755% | CHF 69.8B | CHF 172.55 | 0.88% down | 755% up | ||
| 2 | Kodiak SciencesKOD · Health Care | +396% | CHF 5.3B | CHF 81.24 | 0.30% down | 396% up | ||
| 3 | Twist BioscienceTWST · Health Care | +340% | CHF 6.3B | CHF 93.08 | 1.27% down | 340% up | ||
| 4 | ImmunityBioIBRX · Health Care | +193% | CHF 5.6B | CHF 5.24 | 0.64% down | 193% up | ||
| 5 | Revolution MedicinesRVMD · Health Care | +131% | CHF 29.5B | CHF 136.38 | 0.41% down | 131% up | ||
| 6 | Adaptive BiotechnologiesADPT · Health Care | +88.1% | CHF 3.9B | CHF 24.02 | 0.14% up | 88% up | ||
| 7 | Kymera TherapeuticsKYMR · Health Care | +87.5% | CHF 8.7B | CHF 101.44 | 0.83% down | 87% up | ||
| 8 | CG OncologyCGON · Health Care | +85.3% | CHF 6B | CHF 67.34 | 1.34% up | 85% up | ||
| 9 | ExelixisEXEL · Health Care | +62.6% | CHF 14B | CHF 57.48 | 0.32% down | 63% up | ||
| 10 | BiogenBIIB · Health Care | +49.3% | CHF 30.7B | CHF 207.91 | 1.51% down | 49% up | ||
| 11 | Krystal BiotechKRYS · Health Care | +46.3% | CHF 7.4B | CHF 250.51 | 0.32% down | 46% up | ||
| 12 | ImmunovantIMVT · Health Care | +43.4% | CHF 5.8B | CHF 28.10 | 0.51% up | 43% up | ||
| 13 | Halozyme TherapeuticsHALO · Health Care | +36.6% | CHF 9.2B | CHF 80.38 | 0.51% down | 37% up | ||
| 14 | AmgenAMGN · Health Care | +33.7% | CHF 205.5B | CHF 379.89 | 1.45% down | 34% up | ||
| 15 | Gilead SciencesGILD · Health Care | +32.9% | CHF 175.2B | CHF 141.27 | 1.43% down | 33% up | ||
| 16 | Bio-TechneTECH · Health Care | +25.6% | CHF 9.6B | CHF 61.21 | 0.12% up | 26% up | ||
| 17 | VaxcytePCVX · Health Care | +22.2% | CHF 7.9B | CHF 49.90 | 0.20% down | 22% up | ||
| 18 | Neurocrine BiosciencesNBIX · Health Care | +20.2% | CHF 14.1B | CHF 138.89 | 0.55% down | 20% up | ||
| 19 | Scholar Rock HoldingSRRK · Health Care | +13.6% | CHF 4.5B | CHF 37.27 | 1.77% down | 14% up | ||
| 20 | QiagenQGEN · Health Care | +12.0% | CHF 8.6B | CHF 41.85 | 0.07% down | 12% up | ||
| 21 | RepligenRGEN · Health Care | +4.58% | CHF 9B | CHF 140.57 | 2.97% up | 5% up | ||
| 22 | argenxARGX · Health Care | +3.60% | CHF 50.1B | CHF 797.42 | 0.02% down | 4% up | ||
| 23 | BioNTechBNTX · Health Care | -16.3% | CHF 17.6B | CHF 70.98 | 0.64% down | 16% down | ||
| 24 | CRISPR TherapeuticsCRSP · Health Care | -20.9% | CHF 3.3B | CHF 34.07 | 0.81% up | 21% down |
Sources: share prices and market values from Yahoo Finance; sector, country and category from each company's SEC registration.
Market value is share price × shares outstanding, from Yahoo Finance; prices may be delayed 15 minutes or more and the ranking refreshes about every 20 minutes. The list covers companies with shares listed in the US, which includes foreign companies listed through ADRs but not ones listed only abroad. Sector, category and country come from each company's SEC registration. Sums are converted from US dollars at today's exchange rate (1 USD = 0.8418 CHF).
Questions and answers
Which biotech rank first by one-year price change?
Moderna (+755%), Kodiak Sciences (+396%) and Twist Bioscience (+340%) are the top three of the 24 biotech ranked by one-year price change as of 18 Nov 2026, 14:31 UTC.
How many biotech are in this ranking?
24 are ranked by one-year price change.
What are these biotech worth together?
The 24 biotech ranked by one-year price change have a combined market value of CHF 707.8B as of 18 Nov 2026, 14:31 UTC.
What does ranking by one-year price change measure?
How far the share price has moved over the last 52 weeks.
Learn how this ranking works
All markets guides →- 52-week high and low: what the range tells you
A stock's 52-week high and low are the highest and lowest prices it reached over the past year. Where today's price sits in that range, from 0% at the low to 100% at the high, shows how the past year has gone. Sources differ on whether they use closing or intraday prices, so the same stock's range can differ slightly.
- Drawdown and recovery: why a 50% fall needs a 100% gain
A drawdown is how far a price has fallen from its previous peak, as a percentage of that peak. Recovery needs a larger gain than the fall, because the gain starts from a smaller base: a 20% drop needs a 25% rise to get back, a 50% drop needs 100%, and a 75% drop needs 300%.
- How an ETF's size is measured: AUM, NAV and creation units
An ETF's size is usually measured by its assets under management (AUM), the fund's net assets: everything it holds minus what it owes. That equals net asset value per share times shares outstanding. AUM grows when the holdings rise in value and when large institutions create new shares, and shrinks when they redeem them.
Cite this page
Funkfolio, “Biotech by one-year price change”, data as of 18 November 2026. https://funkfolio.com/companies/category/biotech?by=year-change
Underlying data: Yahoo Finance; SEC EDGAR.